2025

Cooper GW, et al. SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity. Research Square (2025). https://doi.org/10.21203/rs.3.rs-6018128/v1


2024

Mitall KM*, Cooper GW*, Lee BP*, Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Communications Biology 7, 426 (2024). https://doi.org/10.1038/s42003-024-06140-6


2022

Cooper GW, Hong AL. SMARCB1-deficient cancers: novel molecular insights and therapeutic vulnerabilities. Cancers 14, 3645 (2022). https://doi.org/10.3390/cancers14153645

Baptista RP, Li Y, Sateriale A, Sanders MJ, Brooks KL, Tracey A, Ansell BR, Jex AR, Cooper GW, et al. Long-read assembly and comparative evidence-based reanalysis of Cryptosporidium genome sequences reveal expanded transporter repertoire and duplication of entire chromosome ends including subtelomeric regions. Genome Research 32: 203-213 (2022). https://doi.org/10.1101/gr.275325.121

Jones RB, Farhi J, Adams M, Parwani KK, Cooper GW et al. Targeting MLL methyltransferases enhances the antitumor effects of PI3K inhibition in hormone receptor–positive breast cancer. Cancer Research Communications 2, 1569–1578 (2022). https://doi.org/10.1158/2767-9764.CRC-22-0158


2021

Baptista RP, Cooper GW, et al. Challenges for Cryptosporidium Population Studies. Genes 12, 894 (2021). https://doi.org/10.3390/genes12060894